Carolyn Hax: Weight loss praise turns judgmental upon mention of GLP-1 drugs
Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.
Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.
Most people would agree they could shed a few pounds. Not everyone, however, is prepared to stick to a diet or put in the time at the gym. They’d rather take a shortcut, and one of those is Ozempic, hailed by influencers and celebrities as a miracle medicine. Now a doctor has issued a warning, … Read more
Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102, Issue 13 This article explores the significant environmental challenges associated with the rapidly increasing production of popular peptide-based weight-loss drugs like Wegovy and Zepbound. It highlights that current manufacturing methods, primarily solid-phase peptide … Read more
Learn about SYNT-101, the emerging treatment for obesity that combines the best of two proven methods.
A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight loss medication Wegovy. Experts say an oral medication might be easier for people to use, … Read more
(MedPage Today) — GLP-1 receptor agonists for patients with diabetes was not associated with an increased risk for acute pancreatitis, a multicenter analysis found. (American Journal of Gastroenterology) Allogeneic hematopoietic stem cell transplant…
THURSDAY, May 15, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a study published online May 11 in…
Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity. Here are three notes from the secondary analysis: The “Semaglutide and Cardiovascular Outcomes … Read more
Physical activity is essential for body weight maintenance after body weight-loss, partly by promoting the coupling between energy intake and expenditure. However, the underlying mechanisms remain largely unknown. Here we demonstrate that running induces small intestine growth independently of GLP-2. In addition, exercise increases L-cell density in the small intestine and glucose-stimulated GLP-1 secretion, and … Read more